You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Systemic Therapy in Acute Lymphoblastic Leukemia

Guideline Objective

The objective of this evidence summary is to systematically review the available evidence with respect to the following two topics in the treatment of acute lymphoblastic/lymphocytic leukemia (ALL): - The use of pediatric-inspired regimens in the adolescent and young adult (AYA) population. - The use of tyrosine kinase inhibitors (TKIs) in adult patients with Philadelphia chromosome-positive (Ph+) ALL.

Patient Population

The purpose of this evidence summary is to inform care decisions regarding the use of ALL pediatric regimens in the treatment of AYAs with ALL.

Intended Guideline Users

This evidence summary is targeted for all people involved in systemic therapy treatment of patients with ALL.

Research Question(s)

  1. Compared with adult regimens, is there a benefit in the use of pediatric-inspired regimens for the management of non-pediatric patients with ALL?
  2. In the management of Ph+ ALL patients, does the addition of a TKI to the treatment regimen improve patient outcomes?
pdf download pebc12-16es.pdf
Modality: 

Chemotherapy

PEBC: 

PEBC

Guideline Identifier: 

12-16

Cancer Continuum: 

Treatment

Cancer Type: 

Hematologic

Leukemia

Type of Content: 

Guidelines & Advice

Evidence Summary

Authors:  M. Sabloff C. Agbassi K. Howson-Jan Systemic Treatment Disease Site Group Universal Date:  2016-06-22 00:00:00